Navigation Links
Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
Date:8/2/2009

PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) will host a conference call to discuss its exclusive license and collaboration agreement with Purdue Pharmaceutical Products L.P. to commercialize Intermezzo((R)) (zolpidem tartrate sublingual tablet) in the United States. The FDA has established October 30, 2009 as the Prescription Drug User Fee Act (PDUFA) action date for the Intermezzo((R)) New Drug Application (NDA).

Conference Call Information

          Date: Monday, August 3, 2009
          Time: 8:30 a.m. ET
          Dial-in (U.S.): 877-545-1490
          Dial-in (International): 719-325-4864

A simultaneous web cast of the conference call will be available on the Investor Relations section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until Monday, September 7, 2009.

A telephone replay of the conference call will be available beginning August 3, 2009 at 11:30 a.m. ET and ending on August 17, 2009. The replay telephone number is 888-203-1112 (U.S.) or 719-457-0820 (International), Replay Passcode: 5541799.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. For further information, please visit the company's website at: www.transcept.com.

    Contacts:          Transcept Pharmaceuticals, Inc.
                       Greg Mann
                       Director of Corporate Communications
                       (510) 215-3567
                       gmann@transcept.com

                       The Ruth Group
                       Investors / Media
                       Sara Ephraim Pellegrino / Jason Rando
                       (646) 536-7017 / 7025
                       spellegrino@theruthgroup.com
                       jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
2. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
3. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
4. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
5. Transcept Pharmaceuticals Reports First Quarter 2009 Financial Results
6. Transcept Pharmaceuticals Appoints Joseph T. Kennedy as General Counsel
7. Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results
8. Transcept Pharmaceuticals to Report Fourth Quarter 2008 Results
9. Transcept Pharmaceuticals to Present at Two Upcoming Conferences
10. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
11. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... ATA 2017 President’s Awards recipients, comprised of organizations and individuals who have ... , The ATA 2017 President’s Awards recognize individuals and organizations on the ...
(Date:4/26/2017)... ... 26, 2017 , ... Elisabete Miranda, president and CEO of ... Women magazine as one of its 2017 Enterprising Women of the Year, a ... demonstrated that they have fast-growth businesses, mentor or actively support other women and ...
(Date:4/26/2017)... , ... April 26, 2017 , ... Miami native and ... a dentist. , “I could have never imagined back in 1991 that this journey ... Dr. Gallardo. , Over the last 25 years, Dr. Gallardo has pioneered implant dentistry ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively ... dairy proteins, providing direct cost savings as well as more stable pricing over ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus ... that’s the first in a new class of photodynamic cosmetics (PDC). , Allumera® ... skin, visibly reduce outward signs of aging, and minimize the appearance of pores ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most ... the forecast period Mobile X-Ray segment is the ... X-Ray devices market, which is estimated to be valued at ... CAGR of 7% over the forecast period. Mobile X-Ray segment ... US$ 100 Mn in 2017 over 2016. The segment,s revenue ...
Breaking Medicine Technology: